Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
11:20am, Friday, 13'th Feb 2026
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
Novartis Says Vanrafia Drug Slows Kidney Function Decline
01:57am, Friday, 13'th Feb 2026
The pharma major said that phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with progressive autoimmune kidney disease, IgA nephropathy.
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
01:15am, Friday, 13'th Feb 2026
Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treate
First Look: Amazon's $200B Capex, Coinbase's SB Ad, Kroger CEO
07:38am, Monday, 09'th Feb 2026
Stock News Japan rally on election landslide: Japanese stocks hit record highs after Prime Minister Sanae Takaichi's coalition secured a two-thirds lower-house
Oppenheimer Asset Management Inc. Increases Position in Novartis AG $NVS
03:30am, Monday, 09'th Feb 2026
Oppenheimer Asset Management Inc. raised its holdings in Novartis AG (NYSE: NVS) by 6.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and E
Oakmark International Strategy Q4 2025 New Investments And Divestments
12:20pm, Sunday, 08'th Feb 2026
Oakmark International Strategy Q4 2025 New Investments And Divestments
Envestnet Asset Management Inc. Raises Holdings in Novartis AG $NVS
04:46am, Friday, 06'th Feb 2026
Envestnet Asset Management Inc. lifted its position in shares of Novartis AG (NYSE: NVS) by 4.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commissi
Novartis: Value Price, Growth Pipeline
05:51am, Thursday, 05'th Feb 2026
Novartis (NVS) offers a compelling value opportunity with EPS growth, margin expansion, and a robust pipeline at a discounted multiple. NVS is undergoing a slow re-rating, actively buying back shares,
Novartis Q4 Earnings Call Highlights
05:10am, Thursday, 05'th Feb 2026
Novartis (NYSE: NVS) reported full-year 2025 results marked by high single-digit sales growth, double-digit core operating income growth, and the achievement of its 40% core margin target two years ah
Novartis AG $NVS is Cullen Capital Management LLC’s 4th Largest Position
04:26am, Thursday, 05'th Feb 2026
Cullen Capital Management LLC trimmed its position in shares of Novartis AG (NYSE: NVS) by 1.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exc
Hantz Financial Services Inc. Buys 14,342 Shares of Novartis AG $NVS
03:06am, Thursday, 05'th Feb 2026
Hantz Financial Services Inc. raised its stake in shares of Novartis AG (NYSE: NVS) by 53.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange C
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
04:40pm, Wednesday, 04'th Feb 2026
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead
12:25pm, Wednesday, 04'th Feb 2026
Swiss pharmaceutical Novartis AG (NYSE: NVS) reported fourth-quarter 2025 results on Wednesday.
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales
10:36am, Wednesday, 04'th Feb 2026
NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, reshaping its growth mix.
Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Wednesday, 04'th Feb 2026
The headline numbers for Novartis (NVS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estim
